Saturday 17 October 2026 Export IDYA’s income statement to Excel — free account

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024. In the quarter to June 2026, revenue grew 125.8%, EPS fell 38.6% and free cash flow fell 41.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

32.85 1.00 −2.95%

Follow IDYA

Alert me

Market cap: $3.3B
P/E: 0.0×
Fwd P/E: −6.4×
Dividend yield: —
F-score: 4/9
Altman Z: 20.70
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.65

Total sells 1.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	1	—	—	1

Insider Ownership 2.15%

Capital & Financial Ratios $m

Market Cap 3,270.00

Revenue 234.13

Net Income (175.02)

Free Cash Flow (113.87)

Net Debt (828.95)

Current Ratio 10.45

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (6.41)

P/S ratio 12.92

P/B ratio 2.52

Past 5Y EPS Growth —

This Y EPS Growth (260.57%)

Next Y EPS Growth 8.26%

Next Y revenue growth (81.21%)

Next 5Y EPS Growth (29.51%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.97%

10-year low 10-year high

P/B against its own 10 years 56.19%

10-year low 10-year high

EV/Sales against its own 10 years 26.60%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	525	676	639	829
Receivables	0	0	—	—
Inventory	—	—	—	—
Other	—	—	6	15
	533	690	667	864

	2023	2024	2025	Q'26
Payables	7	15	18	31
ST’ Debt	—	—	—	—
Other	—	—	—	—
	27	46	59	83

Compound Annual Growth %

	10y	5y	3y
Sales	—	62.11%	62.54%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	38.84%	43.05%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	7	9	—	—	—
’25	—	—	208	11	219
’24	—	—	—	—	7
’23	8	4	8	4	23
’22	11	6	30	4	51
’21	7	9	9	3	28

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(75)	(88)	—	—	—
’25	(60)	(62)	142	(90)	(71)
’24	(44)	(33)	(49)	(122)	(248)
’23	(28)	(33)	(30)	(24)	(115)
’22	(20)	(20)	(24)	(23)	(87)
’21	(14)	(13)	(12)	(17)	(56)
’20	(10)	(14)	90	(12)	55

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(76)	(89)	—	—	—
’25	(62)	(63)	142	(91)	(73)
’24	(45)	(34)	(50)	(123)	(251)
’23	(28)	(34)	(31)	(25)	(118)
’22	(20)	(22)	(25)	(23)	(91)
’21	(15)	(14)	(13)	(17)	(58)
’20	(10)	(14)	90	(12)	55

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.11)	(1.22)	—	—	—
’25	(0.82)	(0.88)	1.33	(0.94)	(1.28)
’24	(0.53)	(0.68)	(0.60)	(1.49)	(3.36)
’23	(0.49)	(0.50)	(0.46)	(0.52)	(1.96)
’22	(0.36)	(0.57)	0.04	(0.50)	(1.42)
’21	(0.28)	(0.33)	(0.31)	(0.47)	(1.41)
’20	(0.59)	(0.59)	(0.17)	(0.18)	(1.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	4.89	2.95	13.16	8.14	13.29	24.20	13.45	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	16.90	19.97	28.00	24.09	36.51	47.74	37.08
People
People	Employees	—	—	58	47	62	81	103	124	131	145
	Revenue/emp, $m	—	—	0.00	0.00	0.32	0.34	0.49	0.19	0.05	1.51
Income, $m
Income, $m	Revenue	—	—	—	—	20	28	51	23	7	219
	Gross margin, %	—	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	(12)	(34)	(42)	(34)	(50)	(59)	(113)	(274)	(114)
	EBT margin, %	—	0.00	0.00	0.00	(176.55)	(178.10)	(115.17)	(483.05)	(3,921.10)	(51.99)
	Net income	—	(12)	(34)	(42)	(34)	(50)	(59)	(113)	(274)	(114)
	Depreciation	—	0	0	1	2	4	3	(8)	(19)	(5)
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.79	0.79	1.23	0.41	0.09	2.47
	Earnings	—	(17.07)	(35.93)	(3.36)	(1.40)	(1.41)	(1.42)	(1.96)	(3.36)	(1.28)
	Cash flow	—	(17.59)	(28.89)	(3.15)	2.24	(1.58)	(2.10)	(2.00)	(3.03)	(0.80)
	Capex	—	(2.53)	(1.79)	(0.11)	(0.02)	(0.07)	(0.08)	(0.04)	(0.05)	(0.03)
	Free cash flow	—	(20.12)	(30.68)	(3.25)	2.22	(1.66)	(2.19)	(2.04)	(3.08)	(0.83)
	Book value	—	0.00	(51.20)	8.03	8.02	8.55	8.43	10.80	12.97	11.56
	Shares, m	—	1	1	12	25	35	41	58	82	88
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	29.83	14.14	86.63	89.76	13.26
	P/B	—	—	—	—	1.75	2.76	2.06	3.26	1.98	2.99
	EV/Sales	—	—	—	—	0.00	20.99	6.98	64.18	60.84	10.49
	EV/FCF	—	—	—	—	1.14	(10.04)	(3.92)	(12.76)	(5.66)	(32.93)
Cash, $m
Cash, $m	Operating cash flow	—	(12)	(28)	(39)	55	(56)	(87)	(115)	(248)	(71)
	Capex	—	(2)	(2)	(1)	0	(3)	(3)	(2)	(4)	(2)
	Free cash flow	—	(14)	(29)	(41)	55	(58)	(91)	(118)	(251)	(73)
Balance, $m
Balance, $m	Working capital	—	11	85	95	250	206	339	506	644	608
	Total debt	—	3	—	7	7	5	3	—	—	—
	Net debt	—	(13)	(90)	(99)	(284)	(247)	(365)	(525)	(676)	(639)
	Shareholders’ equity	—	—	(49)	100	198	302	349	621	1,059	1,023
Returns, %
Returns, %	ROA	—	(20.81)	(71.15)	(40.06)	(16.77)	(14.64)	(15.25)	(21.78)	(30.95)	(10.18)
	ROIC	—	0.00	0.00	(1,916.16)	0.00	(57.39)	0.00	(87.54)	(53.38)	(25.96)
	ROE	—	36.68	106.19	(163.16)	(23.10)	(19.91)	(18.02)	(23.28)	(32.67)	(10.92)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%	Compare
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	+69.41% (above 0%: growing)	n/m	+288.08% (above 0%: growing)	93.03%	(11.45%)	Compare
VKTX Viking Therapeutics, Inc.	$3.5B	— (loss-making)	—	—	n/m	−165.98% (below 0%: shrinking)	0.00%	0.00%	Compare
ACAD ACADIA Pharmaceuticals Inc.	$3.4B	8.5×	55.6×	+16.40% (above 0%: growing)	+12.50% (above 0%: growing)	+50.32% (above 0%: growing)	90.81%	12.29%	Compare
XENE Xenon Pharmaceuticals Inc.	$3.3B	— (loss-making)	— (loss-making)	+100.70% (above 0%: growing)	n/m	−48.57% (below 0%: shrinking)	100.00%	0.00%	Compare
IDYA IDEAYA Biosciences, Inc.	$3.3B	— (loss-making)	— (loss-making)	+125.77% (above 0%: growing)	n/m	−41.09% (below 0%: shrinking)	100.00%	(1,380.73%)
CELC Celcuity, Inc.	$3.0B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
DNLI Denali Therapeutics Inc.	$2.9B	— (loss-making)	— (loss-making)	−89.74% (below 0%: shrinking)	n/m	−22.91% (below 0%: shrinking)	97.42%	(3,622.11%)	Compare
Median of peers	$3.4B	—	—	+59.33%	—	−33.84%	91.58%	0.00%

All 614 Biotechnology stocks →

IDEAYA Biosciences, Inc. (IDYA) key facts

Strength: IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
IDEAYA Biosciences, Inc. (IDYA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IDYA traded at $32.85, a market capitalization of $3.3 billion.
Return on equity was −10.9% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 20.70 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.